We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Generation Graphene-Based PCT/CRP IVD Test to Give Results Within Minutes

By LabMedica International staff writers
Posted on 20 Jul 2022

The first proof of concept graphene-based diagnostic test to immediately identify patients who need antibiotic treatment is currently under development. More...

The test will be the first in a pipeline of affordable, portable, easy-to-use, graphene-based IVD products, which will at least match the performance of the most advanced hospital laboratory, but at the point of care.

Paragraf (Cambridgeshire, UK) is collaborating with leading UK universities to develop a new generation of graphene-based, in-vitro diagnostic products that will give results within a few minutes. The company is starting a two-year program to develop a proof-of-concept combined PCT (procalcitonin) and CRP (C-reactive protein) test, on a single panel. A clinical study of the combined PCT/CRP test will be delivered at the Diagnostics and Technology Accelerator (DiTA) in mid-2023. DiTA aims to address unmet needs, transform patient care and improve efficiency within the UK NHS, by facilitating the rapid translation and adoption of new innovations into the health and care system. The project is expected to be completed by the end of May 2024.

“This graphene-based diagnostic test is expected to become the first test in the world to give clinicians the ability to identify patients who need an antibiotic treatment within the space of a regular 15-minute clinic appointment. It encourages antimicrobial stewardship by giving clinicians the insight into when not to prescribe antibiotics as the test result differentiates viral from bacterial infections,” said Malcolm Stewart, Paragraf Diagnostics Business Development Director. “Paragraf will go on to deliver a series of high sensitivity, rapid tests for disease biomarkers in areas including cardiovascular disease, oncology, and infectious diseases. The ambition is to develop a comprehensive suite of tests that could be used in almost any environment or healthcare setting. Our tests are designed to provide ultra-fast answers to diagnostic challenges and to reach beyond the concept of point of care testing to create a complete diagnostic toolkit at the point of need.”

“We expect to show that our proposed acute inflammatory marker test will have the capability to deliver accurate results for emergency patient care within a few minutes, from a small sample of blood,” said Paul Dark, Professor of Critical Care Medicine at The University of Manchester. “The accuracy of the test is envisaged to be at least comparable with hospital centralized lab-based immunoassay (antibody) tests which can take hours to provide results back to emergency services.”

“The main benefit of a single PCT and CRP test is that a combined test increases confidence in the accuracy of the result when discriminating between bacterial and other infections,” said Dr. Tim Felton, Director of DiTA. “An accurate test able to provide results that can guide antibiotic therapy in real time is becoming a critical tool in the fight against antibiotic resistance.”

“This technology reduces the time and complexity of sample preparation which, together with its rapid measurement speed, provides clinicians with accurate results in a timeframe that allows immediate decisions to be made on antimicrobial prescribing. This is especially important for the treatment of children and neonates,” added Professor Enitan Carrol, Professor of Paediatric Infectious Diseases at the University of Liverpool.

Related Links:
Paragraf


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.